Charles River Laboratories InternationalCRL
Recorded

Charles River Laboratories International 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 16 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Charles River Laboratories Third Quarter 2026 Earnings Conference Call. This conference call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this period, you will need to press star one on your telephone keypad. If you would like to remove yourself from the queue, please press star two. Lastly, if you should need any operator assistance today, please press star 0. I would now like to turn the conference over to our host, Mr. Todd Spencer, Vice President, Investor Relations.

Todd SpencerVP of Investor Relations

Please go ahead, sir. Good morning, and welcome to Charles River Laboratories Third Quarter 2026 Earnings Conference Call and Webcast.

Todd SpencerVP of Investor Relations

This morning, I am pleased to be joined by Birgit Girshick, our Chief Executive Officer, and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the third quarter of 2026, as well as our financial guidance. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on the Investor Relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor.

Todd SpencerVP of Investor Relations

All remarks that we make about future expectations, plans, and prospects for the company constitute forward-looking statements under federal securities law, including the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated. During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and the reconciliations on the Investor Relations section of our website. I will now turn the call over to Birgit Girshick.

Birgit GirshickCEO

Thank you, Todd, and good morning. We are pleased today to report another solid quarter with revenue and non-GAAP earnings per share that exceeded our prior outlook, continued momentum in the improving biopharmaceutical demand environment, and additional progress towards the execution of our Pathway to Purpose strategic vision. It was wonderful to see many of you at our Investor Day just over one month ago, and I hope that you found it to be an informative discussion about our strategic initiatives designed to enhance our operational excellence and strengthen our scientific leadership, as well as our future growth drivers and long-term financial targets. As I mentioned, our focus is to simplify the company and move faster, invest where we can win, and continue to lead as the scientific partner of choice for the critical work that our clients do.

Birgit GirshickCEO

By executing on these goals, we believe it will translate into higher growth and operating margins and drive long-term shareholder value creation. We have made meaningful progress in recent months on initiatives to support our Pathway to Purpose strategy, which includes working to modernize our company and the industry, strengthening our world-class scientific portfolio, and offering a customized client-centric approach to drive growth. I will now provide you with highlights that demonstrate some of this progress, as well as our third quarter performance. We were encouraged by the acceleration of our revenue growth rate in the third quarter, as we had anticipated, including solid mid-single-digit organic growth in the DSA segment and high single-digit organic growth in the manufacturing segment.

Birgit GirshickCEO

The solid DSA performance was supported by a net book-to-bill of 1.09x in the third quarter, which marks the fourth consecutive quarter that the net book-to-bill has been above one times, averaging approximately 1.1 times over this period. Both the third quarter and trailing 12-month DSA booking performance were consistent with the levels needed to support our long-term financial targets of 5%-7% growth in the DSA segment. With the CDMO business having been divested for a full quarter, we were also pleased to clearly see the underlying growth and margin trends emerge for the manufacturing segment and believe the outlook remains favorable for our comprehensive manufacturing quality control testing solutions. We expect these collective trends to support the improvement to mid-single-digit organic growth for the company in the second half of this year, as well as the projected margin improvement.

Birgit GirshickCEO

To enhance our ability to take advantage of improving demand trends, we are also working on our modernization efforts to drive greater efficiency, including through our Create the Future transformation program. As an example, in July, we implemented a fully automated manufacturing suite for our Endosafe endotoxin cartridge technology to increase cartridge production capacity, strengthen manufacturing controls, and enhance digital traceability. This upgrade improves quality and labor productivity and also increases cartridge production capacity by 14%. Also in our manufacturing segment, we partnered with Autolomous to launch Apollo Orchestrate to digitize laboratory workflows and enhance client connectivity. This is a new capability for our Apollo platform, which will transform laboratory execution systems, increase efficiency, and provide greater transparency and collaboration for clients.

Birgit GirshickCEO

These are two examples of progress in our Create the Future transformation program, which is expected to generate over $300 million in cumulative savings over the next four years and will be a key component to drive meaningful operating margin improvement in 2027 and beyond. We have also taken steps to continue to strengthen our scientific capabilities. We announced a collaboration with the FDA to validate preclinical screening tools to quantify and rank the abuse potential of new drugs. This collaboration is aimed at improving public health by helping to ensure the safety of drugs. As part of our efforts to further advance our Alternative Methods Advancement Project initiative, or AMAP, we also introduced a new rapid cell banking program designed to significantly accelerate product release timelines in the biologics testing business.

Birgit GirshickCEO

By combining rapid cell bank and release packages with advanced characterization using in vitro next-generation sequencing capabilities, we will be able to reduce cell bank production timelines by 40% versus the industry standard of 20 weeks, enabling clients who develop advanced therapies to reach key milestones and bring their innovative treatments to patients faster. In addition, we continue to pioneer in the space of virtual control groups, or VCGs, to selectively reduce animal use where scientifically appropriate. Last week, we announced that our VCG database and methodology will now be used in a GLP-compliant safety assessment study for Ipsen, a biopharmaceutical client. This moves the use of VCGs from concept to regulatory submission. The execution of these kind of initiatives is already benefiting us with clients.

Birgit GirshickCEO

Because of our client-centric approach and the value that we provide to our clients through the global breadth and scientific depth that we are able to offer, we recently extended our relationship with a top 10 biopharmaceutical company to serve as a primary strategic partner for safety assessment services. The incremental work will transition to us over the next 12 to 18 months and meaningfully expand our relationship with this client. With regards to overall demand trends, we are pleased that the improving biopharmaceutical demand environment has remained consistent in recent months and continues to show positive momentum. We are monitoring developments related to inflation, oil prices, interest rates, and the general macroeconomic environment, as well as biotech funding trends for any signs of disruption. But to date, we continue to expect the demand environment to trend favorably.

Birgit GirshickCEO

This view is further supported by our internal demand KPIs, which I will discuss in more detail shortly. Our revenue from both global biopharmaceutical and small and mid-sized biotechnology clients increased on an organic basis in the third quarter. There are several factors contributing to these positive trends. First, many of our large biopharmaceutical clients have progressed through their restructuring activities and are reinvesting in their R&D pipelines, including their preclinical or IND-enabling programs, which is a positive indicator for future demand. In addition, as has been well chronicled, the biotech funding environment has improved meaningfully since the middle of last year, with trailing 12-month funding remaining just below $100 billion despite a modest slowdown in the third quarter. We are not seeing any signs of slowdown in our client interest, supported by another strong increase in DSA proposal activity in the third quarter.

Birgit GirshickCEO

This is an indicator that supports our belief that favorable demand trends will continue. Finally, the DSA bookings improvement over the past four quarters, during which time our net book-to-bill has averaged approximately 1.1x, has begun to work through the backlog, and we're beginning to see the benefits as demonstrated by the improvement in the third quarter revenue growth to the mid-single digits organically for the DSA segment and total company. I will now provide some highlights from our financial performance before Glenn provides additional detail. First, we are pleased that our third quarter results exceeded our prior outlook for revenue and non-GAAP earnings per share. Third quarter revenue increased 4.7% to the highest level since the second quarter of 2023, with a solid performance in both the DSA and manufacturing segments.

Birgit GirshickCEO

The operating margin increased 330 basis points year over year and 260 basis points sequentially to 23% due to operating leverage from higher study volume and lower non-human primate sourcing costs in the DSA segment and the full quarter impact of the divestitures, particularly in the manufacturing segment. Non-GAAP earnings per share of $3.09 increased 27% year over year and also exceeded our prior outlook due to the strong top-line performance and a lower tax rate. Based on our strong third quarter financial performance, we are raising our full-year revenue guidance by 100 basis points to organic growth above 1.5% and non-GAAP earnings per share by $0.15 at midpoint to $11.35-$11.55. As we discussed at our Investor Day, we are pleased to see earnings power return as our growth rate accelerates and we generate meaningful operating margin expansion.

Birgit GirshickCEO

The organic revenue growth rate in each of our business segments also improved from second quarter levels. DSA revenue growth improved to 5.9% organically in the third quarter, primarily driven by robust demand for safety assessment studies utilizing non-human primates, as well as growth for BioA services. As we discussed at our Investor Day, we believe that we have competitive advantages in the areas of non-human primate supply and preclinical BioA services. They are expected to be important growth drivers and differentiators for Charles River in the future, particularly as demand for biologics and other complex therapies continues to intensify. Regarding the DSA pricing environment, we are beginning to modestly reduce the level of discounting in recent proposals. Our goal over time will be to cover annual cost inflation through price increases and receive the value of services that we provide to our clients.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day